CurrentAvMedPolicy N/A

Benlysta (belimumab) subcutaneous prior authorization

Requirements and clinical criteria for pharmacy prior authorization and step-edit approval of Benlysta (belimumab) subcutaneous injection for AvMed members, including initial and reauthorization criteria for SLE and lupus nephritis.

Policy Summary

PayerAvMed

PolicyBenlysta (belimumab) subcutaneous prior authorization

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionSubmit prior authorization with required clinical documentation (labs, SELENA‑SLEDAI or BILAG scores, urine protein/creatinine, renal biopsy when applicable) to support each checked criterion.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

12 monthsAuthorization period

≥5 yrsMinimum age

200 mg wklyStandard dosing

4 / 28 daysQuantity limit

Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

SLE initial criteria

Autoantibody evidence: anti‑nuclear antibody (ANA) titer ≥ 1:80 OR anti‑double stranded DNA (anti‑dsDNA) ≥ 30 IU/mL
Disease activity evidence: SELENA‑SLEDAI score of 6–12 OR ≥2 BILAG B organ domain scores

SLE reauthorization: All initial authorization criteria continue to be met AND member's response to therapy confirmed by ONE of the following: SELENA‑SLEDAI improvement and/or maintained at ≥4 points below baseline OR no new BILAG‑A organ domain score OR no 2 new BILAG‑B organ domain scores; AND absence of intolerable side effects (e.g., serious infections, signs/symptoms of PML, malignancy, severe hypersensitivity/anaphylaxis, or serious infusion reactions).

Initial and reauthorization criteria for Lupus Nephritis

Covered when ALL of the following are met for Active Lupus Nephritis (LN):

LN initial criteria: Prescribed by or in consultation with a Nephrologist or Rheumatologist; member is ≥5 years of age with biopsy‑confirmed Class III, IV, or V lupus nephritis; diagnosis of active, autoantibody‑positive SLE confirmed by ANA ≥1:80 OR anti‑dsDNA ≥30 IU/mL; member has active renal disease and has received standard therapy for the last 90 days with ONE of the following (e.g., mycophenolate, calcineurin inhibitor such as cyclosporine or tacrolimus, cyclophosphamide); provider must obtain a baseline urine protein:creatinine ratio (uPCR) OR urine protein collected within the last 30 days; member does NOT have severe active CNS lupus, current or previous diagnosis of PML, or concurrent use with other biologics; documentation (renal biopsy, labs, chart notes) must be provided.

LN reauthorization: All initial authorization criteria continue to be met AND member has had improvement from baseline and/or stabilization of urine protein:creatinine ratio or urine protein compared to baseline (submit current labs collected within the last 30 days) AND absence of intolerable side effects.

Therapy is not appropriate for members with certain contraindications or limitations. Specifically, members with severe active central nervous system (CNS) lupus, a current or previous diagnosis of progressive multifocal leukoencephalopathy (PML), or those receiving concurrent treatment with other biologic therapies are excluded from approval for belimumab subcutaneous therapy. Documentation must demonstrate absence of these exclusions before authorization is granted.

Reauthorization requires continued absence of intolerable or serious adverse effects. Examples of events that would preclude continued therapy include serious infections, signs or symptoms of PML, malignancy, severe hypersensitivity/anaphylaxis, or serious infusion reactions. Providers must submit relevant chart notes and safety assessments to confirm ongoing suitability for treatment.

For both initial and renewal requests, missing or incomplete documentation regarding these exclusions (or other required clinical evidence) may delay or result in denial of the prior authorization request. Provide clear chart documentation addressing CNS disease activity, prior PML history, and concurrent biologic use as part of the submission.

Initial Therapy and Dosing

Initial therapy dosing

Dosing and initial authorization

Dosing guidance: Adults with SLE: 200 mg subcutaneously once weekly (auto‑injector or prefilled syringe). Adults with lupus nephritis: 400 mg once weekly for 4 doses followed by 200 mg once weekly. Pediatric patients (5 to <18 years, auto‑injector only): patients ≥40 kg — 200 mg once weekly (or 400 mg once weekly for 4 doses then 200 mg once weekly); patients 15 kg to <40 kg — 200 mg once weekly for 4 doses followed by 200 mg once every 2 weeks (alternative induction: 200 mg once weekly). Quantity limit: 200 mg once weekly (4 injections per 28 days).

Continuation / Reauthorization Criteria

Continuation / reauthorization criteria

Reauthorization rules

Reauthorization for SLE: All initial authorization criteria continue to be met AND confirmed clinical response by ONE of the following: SELENA‑SLEDAI improvement and/or maintained at a level ≥4 points below baseline OR no new BILAG‑A organ domain score OR no 2 new BILAG‑B organ domain scores; AND absence of intolerable side effects (e.g., serious infections, signs/symptoms of PML, malignancy, severe hypersensitivity/anaphylaxis, or serious infusion reactions).

Reauthorization for LN: All initial authorization criteria continue to be met AND improvement from baseline and/or stabilization of urine protein:creatinine ratio or urine protein compared to baseline (submit current labs collected within the last 30 days); AND absence of intolerable side effects.

Coding and Monitoring Parameters

SELENA-SLEDAI — disease activity scoring thresholds for baseline and response

Initial disease activity thresholdSELENA-SLEDAI score of 6–12 required to document active SLE at baseline.

Reauthorization / response thresholdImprovement of ≥4 points from baseline on SELENA-SLEDAI (or maintenance ≥4 points below baseline) to confirm response for continuation.

Alternative disease activity evidence≥2 BILAG B organ domain scores may be used instead of SELENA‑SLEDAI to document baseline activity.

ANA titer — required serology threshold

Required ANA titerAnti‑nuclear antibody (ANA) titer ≥ 1:80 required to confirm autoantibody‑positive SLE.

Accepts either serology for diagnosisANA ≥1:80 may be submitted as the sole serologic evidence of autoantibody‑positive disease for SLE or lupus nephritis initial criteria.

DocumentationSubmit lab results showing ANA titer ≥1:80 with the prior authorization request.

anti-dsDNA — required serology threshold

Required anti‑dsDNA levelAnti‑double stranded DNA (anti‑dsDNA) ≥ 30 IU/mL required to confirm autoantibody‑positive SLE.

Alternative to ANAAnti‑dsDNA ≥30 IU/mL may be used instead of ANA ≥1:80 to establish autoantibody‑positive disease for SLE or lupus nephritis.

DocumentationSubmit lab results showing anti‑dsDNA ≥30 IU/mL with the prior authorization request.

Quantity limit — standard adult maintenance dosing / quantity limit

Standard adult maintenance dosing200 mg once weekly (administered via auto‑injector or prefilled syringe).

Quantity limit per monthLimit: 4 injections per 28 days (corresponds to 200 mg once weekly).

Lupus nephritis induction noteFor adults with lupus nephritis induction: 400 mg once weekly ×4 doses followed by 200 mg once weekly (document dosing in request).

Urine protein monitoring — urine protein:creatinine ratio or urine protein within last 30 days requirement

Required baseline urine protein measure for LNProvider must obtain a baseline urine protein:creatinine ratio (uPCR) collected within the last 30 days.

Acceptable alternative specimenA urine protein measurement collected within the last 30 days is acceptable if uPCR is not provided.

Reauthorization monitoringFor reauthorization in LN, submit current uPCR or urine protein collected within the last 30 days demonstrating improvement or stabilization from baseline.

Step-Therapy / Prior Medication Trials

Required prior therapy (must have tried 3)	Established on at least 2 for 90 days (documentation required)
mycophenolate	Must be established on at least two of the listed therapies taken for the last 90 days with chart notes or pharmacy claims documenting trials and insufficient disease control
hydroxychloroquine	Must be established on at least two of the listed therapies taken for the last 90 days with chart notes or pharmacy claims documenting trials and insufficient disease control
azathioprine	Must be established on at least two of the listed therapies taken for the last 90 days with chart notes or pharmacy claims documenting trials and insufficient disease control
cyclophosphamide	Must be established on at least two of the listed therapies taken for the last 90 days with chart notes or pharmacy claims documenting trials and insufficient disease control
methotrexate	Must be established on at least two of the listed therapies taken for the last 90 days with chart notes or pharmacy claims documenting trials and insufficient disease control
cyclosporine	Must be established on at least two of the listed therapies taken for the last 90 days with chart notes or pharmacy claims documenting trials and insufficient disease control
corticosteroids	Must be established on at least two of the listed therapies taken for the last 90 days with chart notes or pharmacy claims documenting trials and insufficient disease control
Other (specify)	Must be established on at least two of the listed therapies taken for the last 90 days with chart notes or pharmacy claims documenting trials and insufficient disease control

Provider Actions and Required Documentation

Prior Authorization

Prior Authorization Required

Prior Authorization Required: Prior authorization is required for Benlysta (belimumab) subcutaneous injection. Approval is granted only when all listed clinical criteria for the requested indication are met. Use of samples to initiate therapy does not meet prior authorization criteria.

Initial and reauthorization period: 12 months
Authorization fax: 1-305-671-0200
Medication supplied by Specialty Pharmacy: Proprium Rx

Documentation Required

Required Supporting Documentation

Required Supporting Documentation: To support each checked criterion the following documentation must be submitted with the prior authorization request. Requests lacking required clinical documentation (labs, diagnostics, chart notes) may be delayed or denied.

Documentation of diagnosis and prescriber specialty (Rheumatologist or Nephrologist as applicable)
Laboratory confirmation of autoantibody-positive SLE: ANA titer ≥ 1:80 OR anti-dsDNA ≥ 30 IU/mL (submit lab results)
SLE disease activity documentation: SELENA-SLEDAI score, ≥2 BILAG B organ domain scores, or other chart documentation of active disease
For lupus nephritis: renal biopsy confirming Class III, IV, or V and baseline renal measurements within last 30 days (uPCR or urine protein)
Evidence of prior/concomitant standard therapies: chart notes showing member tried three listed standard therapies and has been established on two of them for the last 90 days (e.g., mycophenolate, hydroxychloroquine, azathioprine, cyclophosphamide, methotrexate, cyclosporine, calcineurin inhibitors, corticosteroids). Pharmacy paid claims may be used to verify prior therapies
For reauthorization: documentation that initial criteria continue to be met and evidence of improvement or stabilization from baseline (submit current labs within last 30 days)
Documentation of absence of contraindications/limitations: no severe active CNS lupus, no current or prior PML, no concurrent use with other biologics, and absence of intolerable side effects (serious infections, PML signs/symptoms, malignancy, severe hypersensitivity/anaphylaxis, serious infusion reactions)

Note

Form and Administrative Information

Form and Administrative Information: Complete all administrative fields on the prior authorization/step-edit request. Incomplete or illegible requests may delay or result in denial of authorization.

Completed prior authorization form with prescriber signature (preprinted stamps not valid) and date
Member identifiers: Member name, AvMed member number, date of birth
Prescriber information: name, NPI, office contact name, phone and fax numbers
Drug details: drug name/form/strength, dosing schedule, length of therapy, weight and date weight obtained (if applicable), ICD diagnosis code
If information provided is not complete, correct, or legible, the authorization process can be delayed

Definitions

Autoantibody-positive SLE — diagnostic serology criteria (ANA or anti-dsDNA)

Diagnostic serology requirementAutoantibody‑positive SLE is defined by at least ONE of the following: ANA titer ≥1:80 OR anti‑dsDNA ≥30 IU/mL.

Applies to SLE and LN assessmentsEither serologic result may be used to confirm autoantibody positivity for both systemic lupus erythematosus and lupus nephritis criteria.

Documentation instructionSubmit the supporting lab results (ANA and/or anti‑dsDNA) with the prior authorization request.

Active lupus nephritis — biopsy-confirmed Class III, IV, or V with active renal disease and prior therapy

Biopsy confirmationActive lupus nephritis requires renal biopsy confirmation of Class III, IV, or V disease.

Active renal disease and prior therapyMember must have active renal disease and have received standard therapy for the last 90 days with an indicated agent (e.g., mycophenolate, calcineurin inhibitor, cyclophosphamide).

Specialist involvementPrescribed by or in consultation with a Nephrologist or Rheumatologist for lupus nephritis cases.

Quantity Limits

Belimumab subcutaneous — 200 mg once weekly (4 injections per 28 days)

Maintenance dosing and frequencyBelimumab subcutaneous 200 mg once weekly via auto‑injector or prefilled syringe.

Monthly quantity limitQuantity limit set to 4 injections per 28 days (200 mg each).

Formulation noteSupplied as 200 mg subcutaneous injections (auto‑injector or prefilled syringe).

Site of Care and Specialty Pharmacy

Note

Specialty pharmacy dispensing — Proprium Rx; samples not acceptable

Medication is provided by the specialty pharmacy Proprium Rx. Use of samples to initiate therapy does not meet the step‑edit/preauthorization criteria.

Medication dispensed via Proprium Rx specialty pharmacy
Samples do not meet step‑edit or preauthorization requirements

Background

Belimumab (Benlysta) is a B‑cell targeted monoclonal antibody indicated as an add‑on therapy for patients with active, autoantibody‑positive systemic lupus erythematosus (SLE) who are receiving standard therapy, and for adults with active lupus nephritis (Class III, IV, or V) in conjunction with standard therapy. The policy requires laboratory confirmation of autoantibody positivity (either ANA ≥ 1:80 or anti‑dsDNA ≥ 30 IU/mL) and disease‑activity or organ‑specific measures to support use.

Belimumab is provided through the specialty pharmacy program. Note that initiation with manufacturer samples does not meet the policy’s step‑therapy or prior authorization requirements. Prior authorization is required and approval is contingent on meeting the specified clinical criteria and submission of supporting labs, disease activity scores, and chart documentation.